Squarepoint’s Oragenics OGEN Stock Holding History

Squarepoint’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16	Closed	-$13K	–	3473
2020 Q4	$13K	Buy	+16	New	+$14.1K	﹤0.01%	2846
2016 Q4	–	Sell	-1	Closed	-$6K	–	1876
2016 Q3	$6K	Buy	+1	New	+$12K	﹤0.01%	980

Other funds holding OGEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBF

Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAC

Private Wealth Advisors (California) Fresno, California $356M AUM 26.22% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Squarepoint's OGEN Position: Q1 2021 in Review

Squarepoint sold out of Oragenics (OGEN) in Q1 2021, closing a stake of 16 shares — an estimated $13K sold.

Squarepoint first reported a position in OGEN in Q3 2016 and held it in 2 quarters. The position peaked at $13K in Q4 2020. 23 funds tracked by Wall St. Rank hold OGEN as of Q1 2021.

Squarepoint reported no remaining Oragenics position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 16 Oragenics shares in Q1 2021, an estimated $13K.
Squarepoint first reported a position in Oragenics in Q3 2016 and held it in 2 quarters.
Squarepoint's Oragenics position peaked at $13K in Q4 2020.
23 funds tracked by Wall St. Rank held Oragenics as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.